Meta-Analysis on Prevalence and Attribution of Human Papillomavirus Types 52 and 58 in Cervical Neoplasia Worldwide

Objective To estimate the prevalence and attribution of two non-vaccine-covered HPV types (HPV52 and HPV58) across the world. Methods Meta-analysis on studies reported in English and Chinese between 1994 and 2012. Results The pooled prevalence and attribution rates of HPV52 and HPV58 in invasive cervical cancers were significantly higher in Eastern Asia compared to other regions (HPV52 prevalence: 5.7% vs. 1.8–3.6%, P<0.001; HPV52 attribution: 3.7% vs. 0.2–2.0%; HPV58 prevalence: 9.8% vs. 1.1–2.5%, P<0.001; HPV58 attribution: 6.4% vs. 0.7–2.2%, P<0.001). Oceania has an insufficient number of studies to ascertain the prevalence of HPV52. Within Eastern Asia, the attribution of HPV58 to invasive cervical cancer was 1.8-fold higher than that of HPV52. Similarly, HPV52 and HPV58 shared a higher prevalence and attribution among cervical intraepithelial neoplasia in Eastern Asia. In contrast to the classical high-risk type, HPV16, the prevalence and attribution of HPV52 and HPV58 decreased with increasing lesion severity. Thus, HPV52 and HPV58 behave as an “intermediate-risk” type. Conclusion The attribution of HPV52 and HPV58 to cervical intraepithelial neoplasia and invasive cancer in Eastern Asia were respectively 2.5–2.8 and 3.7–4.9 folds higher than elsewhere. Changes in the attributed disease fraction can serve as a surrogate marker for cross-protection or type replacement following widespread use of HPV16/18-based vaccines. This unique epidemiology should be considered when designing HPV screening assays and vaccines for Eastern Asia.

[1]  A. Moscicki,et al.  Geographical distribution and risk association of human papillomavirus genotype 52-variant lineages. , 2014, The Journal of infectious diseases.

[2]  G. Scambia,et al.  HPV vaccine cross-protection: Highlights on additional clinical benefit. , 2013, Gynecologic oncology.

[3]  A. Moscicki,et al.  Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations , 2013, International journal of cancer.

[4]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[5]  V. García-Barriola,et al.  Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study. , 2012, Cancer epidemiology.

[6]  P. Chan,et al.  Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China , 2012, International journal of cancer.

[7]  A. Moscicki,et al.  Identification of human papillomavirus type 58 lineages and the distribution worldwide. , 2011, The Journal of infectious diseases.

[8]  S. Franceschi,et al.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.

[9]  D. Williamson,et al.  Distribution of HPV genotypes in women with cervical cancer in Auckland, New Zealand; a review of 50 specimens between 2000–2006 , 2011, The Australian & New Zealand journal of obstetrics & gynaecology.

[10]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[11]  M. Wong,et al.  Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades , 2009, International journal of cancer.

[12]  S. Garland,et al.  HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia , 2009, Journal of medical virology.

[13]  R. Herrero.  Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. , 2009, The Journal of infectious diseases.

[14]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[15]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[16]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[17]  M. Madeleine,et al.  A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[18]  S. Franceschi,et al.  Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.

[19]  J. Tang,et al.  HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population. , 2007, Gynecologic oncology.

[20]  Che‐kit Lin,et al.  HLA‐B alleles, high‐risk HPV infection and risk for cervical neoplasia in southern Chinese women , 2006, International journal of cancer.

[21]  S. Garland,et al.  Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia , 2005, International Journal of Gynecologic Cancer.

[22]  B. Rose,et al.  Comparative analysis of characteristics of women with cervical cancer in high- versus low-incidence regions. , 2004, Gynecologic oncology.

[23]  K. Kariya,et al.  A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. , 2004, The Journal of infectious diseases.

[24]  P. Chan,et al.  Association of human papillomavirus type 58 variant with the risk of cervical cancer. , 2002, Journal of the National Cancer Institute.

[25]  T. Hwang,et al.  Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. , 1999, Journal of Korean medical science.

[26]  P. Chan,et al.  High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions , 1999, Journal of medical virology.

[27]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[28]  R. Newcombe.  Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.

[29]  Chien-Jen Chen,et al.  Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women , 1997 .

[30]  C. Meinert,et al.  Human papillomavirus and cervical neoplasia: A case‐control study in Taiwan , 1995, International journal of cancer.

[31]  E. B. Wilson.  Probable Inference, the Law of Succession, and Statistical Inference , 1927 .

[32]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[33]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[34]  P. Chan,et al.  Biases in human papillomavirus genotype prevalence assessment associatedwith commonly used consensus primers , 2006, International journal of cancer.

[35]  A. Beckmann,et al.  Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. , 1997, International journal of cancer.

[36]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.